Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st ...

Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of HilleVax in a note issued to investors on Monday, March 31st. HC Wainwright analyst M. Caufield anticipates that the ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

NEW YORK, April 01, 2025--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC ("HCW") announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker’s ...